KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Equity (2016 - 2025)

Acadia Pharmaceuticals has reported Return on Equity over the past 15 years, most recently at 0.13% for Q4 2025.

  • Quarterly results put Return on Equity at 0.13% for Q4 2025, down 21.0% from a year ago — trailing twelve months through Dec 2025 was 0.13% (down 21.0% YoY), and the annual figure for FY2025 was 0.14%, down 25.0%.
  • Return on Equity for Q4 2025 was 0.13% at Acadia Pharmaceuticals, down from 0.3% in the prior quarter.
  • Over the last five years, Return on Equity for ACAD hit a ceiling of 0.35% in Q4 2024 and a floor of 0.52% in Q4 2022.
  • Median Return on Equity over the past 5 years was 0.3% (2021), compared with a mean of 0.15%.
  • Biggest five-year swings in Return on Equity: decreased -22bps in 2022 and later skyrocketed 63bps in 2024.
  • Acadia Pharmaceuticals' Return on Equity stood at 0.3% in 2021, then plummeted by -73bps to 0.52% in 2022, then surged by 70bps to 0.15% in 2023, then soared by 324bps to 0.35% in 2024, then crashed by -62bps to 0.13% in 2025.
  • The last three reported values for Return on Equity were 0.13% (Q4 2025), 0.3% (Q3 2025), and 0.28% (Q2 2025) per Business Quant data.